Turkey · Delayed Price · Currency is TRY IST:BIOEN Statistics
Total Valuation
IST:BIOEN has a market cap or net worth of TRY 7.95 billion. The enterprise value is 13.08 billion.
| Market Cap | 7.95B |
| Enterprise Value | 13.08B |
Important Dates
The next estimated earnings date is Friday, May 8, 2026.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
IST:BIOEN has 500.00 million shares outstanding.
| Current Share Class | 500.00M |
| Shares Outstanding | 500.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 24.40% |
| Float | 227.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.70 |
| PB Ratio | 2.85 |
| P/TBV Ratio | 3.33 |
| P/FCF Ratio | 51.73 |
| P/OCF Ratio | 10.85 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.45, with an EV/FCF ratio of 85.13.
| EV / Earnings | -9.46 |
| EV / Sales | 4.45 |
| EV / EBITDA | 39.45 |
| EV / EBIT | n/a |
| EV / FCF | 85.13 |
Financial Position
The company has a current ratio of 0.31, with a Debt / Equity ratio of 1.87.
| Current Ratio | 0.31 |
| Quick Ratio | 0.11 |
| Debt / Equity | 1.87 |
| Debt / EBITDA | 15.30 |
| Debt / FCF | 33.90 |
| Interest Coverage | -0.97 |
Financial Efficiency
Return on equity (ROE) is -38.07% and return on invested capital (ROIC) is -3.98%.
| Return on Equity (ROE) | -38.07% |
| Return on Assets (ROA) | -3.33% |
| Return on Invested Capital (ROIC) | -3.98% |
| Return on Capital Employed (ROCE) | -7.88% |
| Weighted Average Cost of Capital (WACC) | 6.27% |
| Revenue Per Employee | 3.57M |
| Profits Per Employee | -1.68M |
| Employee Count | 824 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 8.78 |
Taxes
In the past 12 months, IST:BIOEN has paid 610.29 million in taxes.
| Income Tax | 610.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.50% in the last 52 weeks. The beta is 0.06, so IST:BIOEN's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | -7.50% |
| 50-Day Moving Average | 17.60 |
| 200-Day Moving Average | 20.70 |
| Relative Strength Index (RSI) | 39.78 |
| Average Volume (20 Days) | 4,792,077 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IST:BIOEN had revenue of TRY 2.94 billion and -1.38 billion in losses. Loss per share was -2.76.
| Revenue | 2.94B |
| Gross Profit | 99.85M |
| Operating Income | -562.33M |
| Pretax Income | -772.01M |
| Net Income | -1.38B |
| EBITDA | 213.54M |
| EBIT | -562.33M |
| Loss Per Share | -2.76 |
Balance Sheet
The company has 77.61 million in cash and 5.21 billion in debt, with a net cash position of -5.13 billion or -10.27 per share.
| Cash & Cash Equivalents | 77.61M |
| Total Debt | 5.21B |
| Net Cash | -5.13B |
| Net Cash Per Share | -10.27 |
| Equity (Book Value) | 2.79B |
| Book Value Per Share | 5.58 |
| Working Capital | -1.75B |
Cash Flow
In the last 12 months, operating cash flow was 732.44 million and capital expenditures -578.75 million, giving a free cash flow of 153.69 million.
| Operating Cash Flow | 732.44M |
| Capital Expenditures | -578.75M |
| Depreciation & Amortization | n/a |
| Net Borrowing | 137.31M |
| Free Cash Flow | 153.69M |
| FCF Per Share | 0.31 |
Margins
Gross margin is 3.39%, with operating and profit margins of -19.11% and -46.97%.
| Gross Margin | 3.39% |
| Operating Margin | -19.11% |
| Pretax Margin | -26.23% |
| Profit Margin | -46.97% |
| EBITDA Margin | 7.26% |
| EBIT Margin | -19.11% |
| FCF Margin | 5.22% |
Dividends & Yields
IST:BIOEN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -17.39% |
| FCF Yield | 1.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 24, 2021. It was a forward split with a ratio of 3.3333333.
| Last Split Date | Nov 24, 2021 |
| Split Type | Forward |
| Split Ratio | 3.3333333 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |